Next Article in Journal
Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice
Previous Article in Journal
Systemic Therapy in Pediatric-Type Soft-Tissue Sarcoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 27
Issue s2
10.3747/co.27.5549
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer

by
D.E. Meyers
1,2 and
S. Banerji
3,4,*
1
Department of Oncology, University of Calgary, Calgary, AB, Canada
2
Tom Baker Cancer Centre, Calgary, AB, Canada
3
Department of Internal Medicine, Max Rady College of Medicine, Winnipeg, MB, Canada
4
Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(s2), 106-114; https://doi.org/10.3747/co.27.5549
Submission received: 7 January 2020 / Revised: 3 February 2020 / Accepted: 10 March 2020 / Published: 1 April 2020

Abstract

Immune checkpoint inhibitor–based therapies that target ctla-4, PD-1, or the PD-1 ligand PD-L1 have received approval in Canada and many parts of the world for the treatment of melanoma, renal cell cancer, urothelial cancer, classical Hodgkin lymphoma, and non-small-cell lung cancer. However only a small proportion of patients derive long-term clinical benefit. Here, we describe the biomarkers associated with the complex relationship between tumour-related immune stimulus, T cell–mediated immune response, and immune modulation of the microenvironment that can help to predict improved patient outcomes.
Keywords: immune checkpoints; PD-1; PD-L1; ctla-4; biomarkers immune checkpoints; PD-1; PD-L1; ctla-4; biomarkers

Share and Cite

MDPI and ACS Style

Meyers, D.E.; Banerji, S. Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer. Curr. Oncol. 2020, 27, 106-114. https://doi.org/10.3747/co.27.5549

AMA Style

Meyers DE, Banerji S. Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer. Current Oncology. 2020; 27(s2):106-114. https://doi.org/10.3747/co.27.5549

Chicago/Turabian Style

Meyers, D.E., and S. Banerji. 2020. "Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer" Current Oncology 27, no. s2: 106-114. https://doi.org/10.3747/co.27.5549

APA Style

Meyers, D. E., & Banerji, S. (2020). Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer. Current Oncology, 27(s2), 106-114. https://doi.org/10.3747/co.27.5549

Article Metrics

Back to TopTop